GBM is the most common and aggressive malignant brain cancer, with a 5-year survival rate of less than 7%. Despite surgery and radiochemotherapy, recurrence is nearly inevitable and almost always fatal. However, the mechanisms driving treatment resistance and recurrence remain poorly understood. This project aims to profile primary and recurrent GBM pairs, along with matched patient-derived organoid models, using single-cell and bulk sequencing approaches. The goal is to identify cellular populations and regulatory programs enriched or activated in treated samples, providing insights into the underlying mechanisms of treatment resistance and potentially leading to improved outcomes for GBM patients. We also aim to compare matched tissues and organoid models to assess how well these models recapitulate the transcriptional and regulatory features of tumors.
Single-cell multi-omics analysis of primary/recurrent GBM pairs and matched organoid models to investigate mechanisms of treatment resistance
Canada’s Michael Smith Genome Sciences Centre respectfully acknowledges that we operate on the traditional, ancestral and unceded territories of the xʷməθkwəy̓əm (Musqueam), Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh), and Skwxwú7mesh (Squamish) nations who have cared and nurtured this land for all time. We give thanks, as uninvited guests, to be able to live and work on these lands.
